Moody's: U.S. medical device firms face soft organic growth prospects (Mass Device)
U.S. medical products and device makers are likely to pursue share buybacks, dividends and acquisitions to satisfy shareholders and spur growth as demand remains soft and pricing pressure intensifies, Moody's Investors Service said.
Slow organic sales growth is expected over the next 12 to 18 months, though companies facing product-specific challenges or those with more products used for elective procedures are more likely to buy back shares or pursue acquisitions., Moody's said. The rating fir...
